Eli Lilly to spend $27 billion to bolster U.S. drug manufacturing as Trump tariffs loom

[
The push to onshore manufacturing was already underway at Lilly, which has been investing heavily to boost production capacity for Zepbound and Mounjaro. Read More
https://fortune.com/img-assets/wp-content/uploads/2025/02/GettyImages-2092480316-e1740584506716.jpg?resize=1200,600
https://fortune.com/2025/02/26/eli-lilly-us-manufacturing-plants-overseas-zepbound-mounjaro-trump-tariffs/


Madison Muller, Bloomberg